ANNUAL REPORT 2011

Statistical Highlights 2011

Regulatory Mandate

Compliance

• 109 new patented drug products for human use reported to the PMPRB
  • 86 were within Guidelines
• In total, 1,282 patented drug products for human use were under the PMPRB´s jurisdiction

Enforcement

Up to May 31, 2012:

• 15 Voluntary Compliance Undertakings accepted 
• Three hearings completed: ratiopharm Inc.; ratio-Salbutamol HFA; and Copaxone Redetermination
• Decisions pending in two hearings: Sandoz Canada Inc.; and, Pentacel and Quadracel
• Two matters remain before the Board: Apotex Inc. and Apo-Salvent CFC Free

Reporting Mandate

Sales Trends 

• Sales of patented drug products increased by 1.7% to $13.1B
• The share of patented drug products as a percentage of total sales rose slightly from 58.0% in 2010 to 59.1% in 2011
• Antineoplastics and immunomodulating agents made the largest positive contribution to sales growth while products related to the cardiovascular system had the largest decline

Patented Drug Price Trends

• Prices of patented drug products sold by patentees, as measured by the Patented Medicines Price Index, remained on average unchanged while the Consumer Price Index rose by 2.9% 
• Canadian prices were the fourth highest among the seven comparator countries, lower than prices in Switzerland, Germany and the US.

Research and Development 

• Patentees reported total R&D expenditures of $991.7 million, a decline of 15.8% over 2010
• Rx&D members reported $901.2 million in R&D expenditures, a 9.9% decline over 2010
• R&D-to-sales ratios declined in 2011:
  • all patentees, from 6.9% in 2010 to 5.6%
  • Rx&D members, from 8.2% to 6.7%
    

Table of Contents   Next >>